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OX IDATIVE str e ss  in  the  lung is  im portant in  the
pathogenes is  of COPD. Published data in dicate that
glucocor ticoids  inh ibit blood ce lls  in  their  capacity to
produce  reactive ox ygen specie s  (ROS). We inve sti-
gated the effect of Fluticasone  propionate (FP) on the
ROS production  capabilities  of pulm onary cells . Bron-
choalveolar lavage (BAL) was per form ed in  sm oking
COPD patien ts , before and after  a s ix  m onth , placebo-
con trolled treatm ent w ith FP. BAL cells  w ere s tim u-
lated w ith phorbol m yr is trate acetate (PMA ) alone,
and together w ith  superox ide  dism utase (SOD). From
kinetic  plots  of ferricytochrom e-c convers ion  we
calculated th e m ax im al rate of superox ide produc-
tion : Vm a x . We  also  ex am ined BAL cell subsets  and
per form ed corre lation  analyse s  on  ROS production
and relevan t clin ical determ in an ts . Pair ed results
w ere obtain ed from  6 FP- and 9 placebo-treated
patien ts . No s ignificant change  of Vm a x w as found in
both  patien t groups. Also BAL cellularity w as  unchan-
ged. Corre lation  analyse s  show ed a s ignificant
(inverse ) as sociation  of Vm a x w ith th e num ber of
cigarettes  sm oked per day. We concluded that a
poten t inhaled glucocorticoid had no e ffe ct on the
ROS production  capability  of BAL cells  from  sm oking
COPD patients . Apparently, h eavy sm oking im pair ed
the  ability  of alveolar m acrophages  to produce ROS,
w hich was not further decreased by FP.
Key w ords: Reactive ox ygen specie s, Bronchoalveolar
lavage , Fluticasone propionate , Inhaled glucocorticoid,
Chronic obstructive pulmonary dise ase, Smoking
Introduction
The airw ays and alveoli of patients  w ith chronic
obstructive  airw ays disease (COPD) are  invaded w ith
numerous inflammatory cells, w hich have  the  ability
to produce reactive  ox ygen spec ie s  (ROS).1 It has
been established that an incre ased ox idative  stress is
one of the major pathogenic  mechanisms.2 ,3 Ox ida-
tive stress may occur e ithe r by an incre ased ex posure
to ROS or by a decreased capacity of the  involved
tissue to neutralise  the constantly-emerging produc-
tion of ROS. Both mechanisms seem to be involved in
the development of COPD. The smoking of cigarettes
is clearly re lated to COPD. Cigarette  smoke  contains
several molecules, w hich are  ROS by themselves, and
it also contains molecules  and particulate s, w hich
generate chemical reactions and inflammation, w ith
subsequent ROS production.4
A major goal in the treatment of COPD is the
reduction of the number and /or the ac tivity of
inflammatory cells. In asthma patients, glucocor-
ticoids have been applied succe ssfully w ith this
intention. In the  pre sent study, w e have inve stigated if
a pote nt inhaled glucocorticoid (Fluticasone propio-
nate, FP) could reduce  the ROS production in COPD
patients. We have se le cte d COPD patients w ith
bronchial hyperrespons iveness  (BHR) because  these
patients have  an ex aggerated decline  of the ir lung
function. We  hypothe sized that inflammation and ROS
production in this subgroup of COPD patients w ere
severe , and could be influenced by an inhaled
glucocorticoid. Inflammatory cells w ere  collec ted by
means of bronchoalveolar lavage (BAL), before  and
after tre atment w ith inhaled FP or placebo. Be sides
ce ll counts, the ROS production capability w as
dete rmined in v itro . Furthermore, w e analyzed the
association of ROS production capability w ith smok-
ing behaviour, airw ays obstruction and BHR.
Material and methods
Patients
COPD patients w ere  se lected ac cording to the  clinical
and func tional crite ria, w hich are  generally
accepte d.5 Inclusion c riteria w ere : age be tw een 40
and 70 years , current smoker, FEV1 /iVC ratio £ 70% of
predicted normal value s (pred ), reve rsibility of
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FEV1< 10%pred after 750 m g te rbutaline , non-specific
BHR – defined by a PC20 histamine £ 8 mg/ml – and
negative skin tests for standard inhaled allergens.
Refe re nce  value s w ere  obtained from ECCS stan-
dards.6 The  main ex clusion c riteria we re  a history of
asthma and recent respiratory trac t infe ction. Any
anti-inflammatory drugs, including ste roids and
NSAIDs, and theophylline s w ere  discontinued. Poten-
tial candidates  for this  study w ere  informed about the
negative e ffec ts of smoking, and w e  offered them the
opportunity to partic ipate in a smoking-cessation
program. The Hospital’s Medical Ethic s Committe e
approved the  study. Written informed consent w as
obtained from all partic ipants.
Design of the intervention study
We performed a double blind, placebo-controlled
study that lasted for six  months. Patients  we re
randomly assigned to e ithe r tw ic e-daily 500 m g FP or
placebo, w hich were  delivered via a s imilar diskhaler.
The start of treatment w as immediately after the first
bronchoscopy. Bronchoscopy w as repeated at the
end of the  study. At intervals of four weeks, the study
participants  had a check-up.
Bronchoscopy
The procedure w as carried out ac cording to inter-
national guidelines.7 For local anae sthesia w e used
lidocaine spray and ae rosolised ox ybuprocaine. The
bronchoscope  (Olympus BF 1T10) w as advanced into
the late ral segment of the  middle  lobe, in w edge
position. Lavage  w as pe rformed success ive ly w ith
1 ´ 40 ml and 4 ´ 50 ml ste rile  phosphate-buffe red saline
(PBS) solution (Organon Teknika, Box te l, The Nether-
lands ) at body temperature (37°C) and pH 7.4.
Aliquots w e re  aspirated in tw o siliconized spec imen
traps, one for the first ‘bronchoalveolar frac tion’ after
40 ml PBS and the second ‘alveolar fraction’ for the
recovery of the 4 ´ 50 ml PBS. The lavage  fluid w as
transported to the laboratory on ice  and proce ssed
immediately. The recovery of the first, bronchoalveo-
lar frac tion appeared to be low  and insufficient for
performing the desired ex periments.
Processing of BAL fluid
After measurement of volume , the  BAL fluid w as
filtered through sterile  nylon gauzes and centrifuged
at 400 ´ g (4°C for 5 min). The ce ll pe llet w as w ashed
in PBS supplemented w ith 0.5% bovine  serum albu-
min. The total ce ll number in the  BAL cell suspens ion
w as counted in a Coulter Counte r Model ZM (Coulter
Elec tronics, Hialeah, FL, USA) and viability was
asse ssed by cellular ex clusion of trypan blue . With
FACScan flow-cytometry (Becton Dickinson, San Jose,
CA, USA) we  analyzed CD3+ T-cells. Immunocy-
tochemistry of cytospins was carried out w ith the
APAAP (alkaline phosp-hatase anti-alkaline  phospha-
tase ) method w ith monoclonal antibodies CD68
(alveolar macrophage s ), CD15 (VIM-D5, neutrophils ),
and BMK–13 (eosinophils ). Tw o independent obser-
vers counted at least 300 ce lls  in e ach cytospin.
Superoxide production assay
ROS production of BAL cells w as  determined by the
kinetic  mic roplate assay of superox ide  dismutase
(SOD)-inhibitable  fe rricytochrome-c  (0.16 mM horse
heart cyto-chrome-c, Sigma) re duc tion in a 96-we ll
mic roplate (Falcon 3072, Be cton Bickinson, Lincoln
Park, NJ). The cells, at a density of 1 ´ 105 /w ell, w ere
stimulated, in the absence  and presence of SOD, w ith
8 nM and 80 nM phorbol 12-myristate  13-ace tate
(PMA) at 37°C. At 18 seconds inte rvals the change in
absorbance  at 550 nm (1 nm bandw ith ) was read
during 20 min in a Thermomax  mic roplate reader
(Molecular Device s, Sopachem, Lunte ren, The Nether-
lands ), using 540 nm (10 nm bandw ith ) as a re ference
w avelength. All measurements w ere  pe rformed in
duplicate . Using the softw are programme SOFTmax
PRO the  max imum ve loc ity (Vm ax ) of ferricyto-
chrome-c  re duc tion w as dete rmined by calculating
the first derivative of the  absorbance time course in
each w ell, and nex t ex pre ssed as nmol of supe rox ide /
min/106 ce lls, using the diffe rence in Vm ax in the
presence and absence  of SOD, the reduced minus
ox idized cytochrome-c ex tinction coe fficient of
21.1 mM–1 cm–1 , and the empirically dete rmined light
path length. Since  w e found the Vm ax upon stimula-
tion w ith 80 nM PMA did not inc rease further as
compared to 8 nM PMA, apparently the  ce lls  w ere
alre ady max imally stimulated at the lowest PMA
concentration. There fore , w e pre sent these data as
the mean and do not re fer to the  PMA
concentration.
Statistical analysis
Pre- and post-inte rvention data w ere  tested for sig-
nificant diffe re nce  w ith the  paired t-te st. Diffe rences
betw een patient groups were  te sted w ith either the
(unpaired) Student t-te st or the Mann–Whitney te st,
depending upon distribution of data. Correlation
studies  w ere  performed w ith the  Spearman rank te st.
Statistical s ignificance w as  considered at p< 0.05.
Results
From the initial 23 participants  in the inte rvention
study, paired results w ere  obtained from 6 FP patients
and from 9 patients w ith placebo. The reasons for
miss ing paired data w ere  insuffic ient recovery of
either BAL fluid or BAL cells. The patient character-
istic s (n =15), liste d in Table  1, show  that on average
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these  patients  had moderate ly severe  obstruc tive
airw ays disease  and severe  BHR. Compliance  w ith
study medication w as  high: the  pe rcentage of
returned used blisters  w as 92.5 in the FP and 92.7 in
the placebo group.
Difference s in base line charac teristics betw een the
FP and the  placebo group w ere  not statistic ally
significant. In the placebo group, mean FEV1 decline d
from 68.5%pre d at the  start of the trial to 52.0%pre d
after 6 months. Howeve r, lung func tion remained
unchanged in the FP group (mean FEV1 : 72.4 and
69.1%pre d, re spectively). This  treatment e ffec t w as
statistically significant, and considered as  a benefic ial
effect of FP treatment.
Immunocytology
Mean total c ell number of the BAL at the  start of the
trial w as  53.0 ´ 106 for FP treated patients and
45.3 ´ 106 in the placebo group (Table 2 ). Small
changes w ere  noticed in the BAL cell numbers at the
end of the trial, w hich w ere  not significant (Table 2 ).
The pe rcentages of fluid re covery, c ell viability and
ce ll types we re  not statistic ally different betw een
both patient groups, be fore  intervention, and did not
change s ignificantly afte r 6 months of inte rvention
(Table  2 ). The low  number of eosinophils indicates
that COPD w as stable in nature .
ROS production capability
Figure 1 show s Vm ax of the patients from the  FP and
the placebo group, before  and after inte rvention.
Vm ax ranged from 0.076 to 0.753 (mean 0.35)nmol
supe rox ide /min/106 cells in the  FP tre ated patients,
and from 0.06 to 0.67 (mean 0.303) in the  p lacebo
group. Statistic al analysis show ed that there  w ere  no
significant changes after FP or placebo.
Association of Vm ax with airways obstruction,
BHR and smoking status
There w ere  no significant correlations betw een pre-
tre atment Vm ax on the one  hand, and FEV1 and PC2 0
on the  other. How eve r, the ac tual number of c igar-
ettes  smoked pe r day correlated significantly w ith
pre-treatment Vm ax (Fig. 2, R=–0.67, p=0.007, Spear-
man rank te st). There  w as no s ignificant corre lation of
Vm ax and packyears of smoking.
Discussion
In this double  blind, placebo controlled trial, w e
observed no significant e ffec t of a potent inhaled
glucocorticoid on the ROS production capability
(Vm ax ) of BAL ce lls  de rived from a subgroup of COPD
patients, namely those w ith bronchial hype rrespon-
sivene ss. At first glance , this  re sult appears to be
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Table 1. Patient characteristics (mean ±SD)
Fluticasone propionate Placebo
N 6 9
Age 56 ± 7 57 ± 9
Cigarettes/day 17 ± 8 15 ± 5
Packyears 25 ± 12 27 ± 10
FEV1%pred 72 ± 12 68 ± 13
FEV1 reversibility 4.6 ± 2.4 5.3 ± 2.4
PC20 histamine 3.3 ± 3.2 0.8 ± 0.6





Fluid recovery, % 60 ± 13 62 ± 11 54 ± 16 51 ± 19
Cell number, 3 106 53 ± 13.5 59 ± 31 45.3 ± 22.7 36.4 ± 18
Cell viability, % 62 ± 12 66 ± 12 70 ± 13 67 ± 12
CD68+ macrophages, % 95 ± 3 95 ± 4 95 ± 4 91 ± 5
CD15+ granulocytes, % 2.4 ± 2.8 1.9 ± 1.2 3.1 ± 2.8 4.2 ± 7.5
BMK13+ eosinophils, % 0.4 ± 0.3 0.8 ± 0.5 0.4 ± 0.3 0.8 ± 1.0
CD3+ T-cells, % 2.0 ± 2.9 0.7 ± 0.9 3.0 ± 2.9 3.0 ± 6.5
FIG. 1. Results of the superoxide production assay.
Vm ax : maximum velocity of reactive oxygen species pro-
duction, nmol/min/106 cells; FP: Fluticasone propionate; Plac:
placebo; pre: pre-intervention; post: post-intervention.
re lated to the absence of a decre ase in the number of
inflammatory cells in the BAL. Our correlation studie s
indicated that actual smoking status is an important
confounding fac tor. With inc re as ing number of c igar-
ettes  smoked per day, Vm ax decrease s.
As the re  has not been published a similar study in
COPD patients be fore , w e compared our re sults w ith
studies  concerning the effe cts  of glucocorticoids on
ROS production capac ity of blood-derived cells, and
w ith studies concerning the effect of smoking.
In one study, the  superox ide production by PMA-
stimulated blood granulocyte s, taken from 18 mis-
ce llaneous patients  on oral glucocorticoid treatment,
w as dec re ased as  compared to healthy controls .8
Superox ide production by blood granulocytes of
patients w ith emphysema w as  decre ased afte r in  v ivo
prednisolone treatment.9 How eve r, dex amethasone,
both in  v itro and in v ivo , did not alter the sponta-
neous superox ide re lease  of blood granulocyte s from
healthy volunteers.1 0
The  reported studies  concerning the effe ct of
smoking on ROS production capability are  not con-
sis tent. Alveolar macrophage s (AM) from healthy
smokers produced more  superox ide than AM from
nonsmoking control subjec ts.1 1–13 Ex posure to
tobacco smoke  in vitro inc re ased the ox idative
metabolism of AM,14 w hile it reduced superox ide
generation by blood granulocytes .15 Hoidal e t a l.
used almost the  same lavage method as in our
study, and compared young asymptomatic smoke rs
w ith nonsmoke rs.1 1 They re ported that BAL cells
from smokers, stimulated w ith PMA, produced on
ave rage  1.93 nmol ROS/min/106 cells, w hile  BAL
ce lls  from nonsmoke rs produced 0.945 nmol ROS/
min/106 ce lls . We  found an average  (pre-inte rven-
tion) ROS production of 0.322 nmol/min/106 cells
(n=15). The  low  ROS production capability in our
study could either be due to patient se le ction
(COPD), the pre sence of BHR, diffe rent BAL ce ll
counts or to smoking. ROS production by BAL cells
from smokers  w ithout COPD w as not diffe re nt
from smokers  w ith COPD.16 Therefore , the  diag-
nosis of COPD seems to be  unimportant. Fur-
thermore, s ince  the leve l of PC20 w as not sig-
nificantly correlated w ith Vm ax , and the ce ll profile
in BAL resemble s the  reported findings in ‘average’
COPD patients and smokers , the  first three  options
are  not likely. How eve r, our corre lation analyses
indicate that c igarette  smoking influences ROS pro-
duc tion capability. A possible  ex planation could be
that viable  macrophage s lose the ir ability to
re lease  superox ide after repeated stimulation.1 7 This
w as attributed to ligand-induced de sensitisation of
specific re ceptors . This phenomenon might also
have occurred in our heavy smoking COPD
patients.
In conclusion, the BAL cells from smoking COPD
patients w ith BHR, consisting mainly of alveolar
macrophage s, have  a low  ROS production capability.
This w as not furthe r dec re ased by in v ivo ex posure to
a potent inhaled glucocorticoid. The  low  ROS produc-
tion capability might be one  of the  causative  mecha-
nisms of the increased susceptibility to re spiratory
tract infec tions and the increased frequency of
bacte rial colonisation of the airw ays in these  COPD
patients.
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